Also listed on Molecure S.A., an earlier holder on the record. The recorded assignments below show how it moved.
Term ends Sep 25, 2040 · High confidence
20-year base term ends Sep 25, 2040
Held by Oncoarendi Therapeutics S.A.
Filed Sep 25, 2020 as application 17/032,232 · Granted Sep 5, 2023
Base term, 20 years from filing
Today
2020
2040
Clock starts
Sep 25, 2020
Sep 25, 2020
Term ends
Sep 25, 2040
Sep 25, 2040
Granted
Sep 5, 2023
Sep 5, 2023
base term
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
0 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
2
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. 0 of 3 maintenance fees are paid so far. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Sep 25, 2020, when this application, 17/032,232, was filed | Sep 25, 2040 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 0 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Sep 25, 2040 | High confidence |
This family
| US 11,746,107 | this patent Sep 2040 | Sep 2040 |
| US 12,319,677 | In force Sep 2040 | Sep 2040 |
The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Jul 15, 2021 Reel 56869, frame 475 | Witkowski, Grzegorz; Magdycz, Marta; Tyszkiewicz, Magdalena; Pikul, Stanislaw | Oncoarendi Therapeutics S.A. | Assignment of Assignor's Interest |
| Feb 15, 2022 Reel 59020, frame 896 | Galapagos N.V. | Gilead Sciences, Inc. | Security Interest |
| Aug 4, 2022 Reel 61072, frame 709 | Oncoarendi Therapeutics S.A. | Molecure S.A. | Change of Name |
| Feb 17, 2023 Reel 62733, frame 145 | Gilead Sciences, Inc. | Galapagos N.V. | Release of Security Interest |
| Mar 22, 2023 Reel 63893, frame 609 | Zakrzewski, Marcin | Oncoarendi Therapeutics SP Z O.O. | Employment Agreement |
| Jun 8, 2023 Reel 63915, frame 732 | Oncoarendi Therapeutics SP Z O. O. | Oncoarendi Therapeutics S.A. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Sep 2040
Term ends Sep 25, 2040. Maintenance fees still fall due before then
Citations
1
later US patent cites this one
That is below the median of utility patents granted in 2023 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.